Electra Therapeutics, Inc.
No enriched coverage for $ETRA in the last 7 days.
OrbiMed Advisors disclosed an 11.0% stake in Electra Therapeutics (ETRA) following its IPO. The firm acquired the shares for investment, not control, and agreed to a 180-day lock-up period. OrbiMed is a healthcare-focused investment advisor.
GORDON CARL L purchased 1,333,333 indirectly-held shares of Electra Therapeutics, Inc. (ETRA) at $15.00 ($20.00M total) across 2 trades on 2026-09-21.
Electra Therapeutics (ETRA) reports that OrbiMed funds converted preferred shares into 5.55M common shares and purchased 1.33M additional shares at $15 each during its IPO on September 21, 2026. OrbiMed Advisors, a director and 10% owner, disclaims beneficial ownership except for pecuniary interest.
Recent ETRA coverage spans financial news, insider activity and corporate actions.
In the last 30 days, ETRA insiders filed 4 SEC Form 4 transactions — 4 purchases ($40.0M) and no sales. The most active reporter was GORDON CARL L with 2 filings.
The large stake signals strong investor confidence and may attract other investors, potentially supporting the stock price.
Significant insider purchase signals confidence and may support price appreciation.
Significant insider buying signals confidence in post‑IPO valuation and may support short‑term price appreciation.
Significant insider purchase suggests confidence and may support short-term upside.
Insider sale by a senior officer may signal negative sentiment but size is modest for a micro‑cap.
AlphAI scores every news story that mentions ETRA with an AI model for sentiment and relevance, and aggregates insider trades from Electra Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
OrbiMed Advisors disclosed an 11.0% stake in Electra Therapeutics (ETRA) following its IPO. The firm acquired the shares for investment, not control, and agreed to a 180-day lock-up period. OrbiMed is a healthcare-focused investment advisor.
1 min readGORDON CARL L purchased 1,333,333 indirectly-held shares of Electra Therapeutics, Inc. (ETRA) at $15.00 ($20.00M total) across 2 trades on 2026-09-21.
1 min readElectra Therapeutics (ETRA) reports that OrbiMed funds converted preferred shares into 5.55M common shares and purchased 1.33M additional shares at $15 each during its IPO on September 21, 2026. OrbiMed Advisors, a director and 10% owner, disclaims beneficial ownership except for pecuniary interest.
2 min readORBIMED ADVISORS LLC purchased 1,333,333 indirectly-held shares of Electra Therapeutics, Inc. (ETRA) at $15.00 ($20.00M total) across 2 trades on 2026-09-21. Filed jointly with OrbiMed Capital GP VII LLC (Director) and OrbiMed Genesis GP LLC (Director).
1 min readElectra Therapeutics, Inc. (ETRA) reported insider trading activity. A Chief Technical Officer acquired 63,656 shares of common stock and Series A Convertible Preferred Stock on 09/21/2026, according to an SEC Form 4 filing.
1 min readElectra Therapeutics (ETRA) disclosed that director Nancy Stagliano converted 255,635 Series A Convertible Preferred Shares into Common Shares on a 1-for-1 basis following the company's IPO. The conversion was automatic and left her with 255,635 Common Shares.
1 min readElectra Therapeutics' CEO converted 455,484 Series A preferred shares into common stock, with 73,147 shares subject to future vesting. The conversion occurred on September 21, 2026, as part of the company's initial public offering. The preferred stock converted on a one-for-one basis with no expiration date.
1 min readElectra Therapeutics, Inc. (ETRA) filed an SEC Form 8-K — Other Events. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Amendment and Restatement of Certificate of Incorporation On September 21, 2026, in connection with the closing of the initial public offering (the “IPO”) of shares of common stock of Electra Ther
1 min readElectra Therapeutics (ETRA) began trading on Nasdaq on 18 September 2026, raising $350 million via an upsized IPO priced at $15.00 per share. HBM Healthcare Investments, which backed Electra with $30 million, now holds a 3.9% stake valued at $32.8 million. Electra's lead product, ipsoprubart, is in Phase 2/3 trials for sHLH and has received FDA and EMA designations.
2 min readElectra Therapeutics, a biotech company focused on precision immunology, raised $350M in an upsized IPO, pricing 23.3M shares at $15 each. Its lead drug, ipsoprubart, is in Phase 2/3 trials for sHLH. Shares closed at $13.25, down 12% from the IPO price. The company plans to use proceeds for clinical development and commercialization.
2 min read
